US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Opiant Pharmaceuticals Inc (OPNT)
Opiant Pharmaceuticals Inc (OPNT) ニュース

OPNT

Opiant Pharmaceuticals (OPNT)

Opiant Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:OPNT

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2023/03/13	19 : 16	Edgar (US Regulatory)	Termination of Registration of a Class of Security Under Section 12(g) (15-12g)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/10	20 : 05	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/07	04 : 02	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/07	03 : 56	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/07	03 : 17	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/07	03 : 14	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/07	03 : 10	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/07	03 : 07	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/07	03 : 02	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/03	23 : 27	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/03	23 : 25	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/03	23 : 23	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/03	23 : 21	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/03	23 : 20	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/03	23 : 17	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/03	23 : 11	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/03	23 : 09	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/03	23 : 06	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/03	23 : 01	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/03/03	22 : 57	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/02/28	06 : 05	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/02/17	07 : 14	Edgar (US Regulatory)	Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/02/08	06 : 01	GlobeNewswire Inc.	Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/02/07	02 : 14	Edgar (US Regulatory)	Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/02/06	22 : 00	GlobeNewswire Inc.	Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/02/01	06 : 23	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/02/01	06 : 22	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/02/01	06 : 20	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/01/20	06 : 05	GlobeNewswire Inc.	Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose	NASDAQ:OPNT	Opiant Pharmaceuticals Inc
2023/01/10	07 : 17	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPNT	Opiant Pharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:OPNT

1 2 3 4 5 6 7 8 9 10 次へ >>

Health Care Select Sector

Verizon Communications

Deutsche Telekom (QX)

American Express

Financial Select Sector

BNP Paribas (QX)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約